In this course, we will learn of the modern regulatory paradigm of Science-based and Risk-based approaches to drug development (as reflected in ICH Q8 onwards), and of best practices to employ in order to fully harness the benefits of that approach, within fully outsourced and virtual operations.
Share This Event